| 05/14/2026 4:33 PM | Mymd Pharmaceuticals (1321834) Issuer Voss Chelsea Sierra (2108237) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/29/2026 4:19 PM | Mymd Pharmaceuticals (1321834) Filer | Form 10-K/A | |
| 04/15/2026 5:29 PM | Mymd Pharmaceuticals (1321834) Issuer Silverman Joshua (1524858) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/15/2026 5:29 PM | Bernstein Bruce (1665472) Reporting Mymd Pharmaceuticals (1321834) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/15/2026 5:29 PM | Mymd Pharmaceuticals (1321834) Issuer White Billy Joe (1546805) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/15/2026 5:29 PM | Glass Mitchell (2023649) Reporting Mymd Pharmaceuticals (1321834) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/15/2026 5:29 PM | Friscia Stephen (2028845) Reporting Mymd Pharmaceuticals (1321834) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/15/2026 5:29 PM | Mymd Pharmaceuticals (1321834) Issuer Voss Chelsea Sierra (2108237) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/15/2026 4:20 PM | Mymd Pharmaceuticals (1321834) Filer | Form 10-K Annual report pursuant to Section 13 or 15(d) | |
| 03/31/2026 3:30 PM | Mymd Pharmaceuticals (1321834) Filer | Form NT 10-K | |
| 03/13/2026 3:30 PM | Mymd Pharmaceuticals (1321834) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
Get the Latest News and Ratings for QCLS and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Mymd Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.
|
| 02/17/2026 11:15 PM | Mymd Pharmaceuticals (1321834) Filer | Form EFFECT | |
| 02/11/2026 4:17 PM | Mymd Pharmaceuticals (1321834) Filer | Form S-3 Registration statement under Securities Act of 1933 | |
| 01/30/2026 4:30 PM | Mymd Pharmaceuticals (1321834) Issuer Voss Chelsea Sierra (2108237) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 01/30/2026 4:31 PM | Mymd Pharmaceuticals (1321834) Issuer Voss Chelsea Sierra (2108237) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/23/2026 4:00 PM | Mymd Pharmaceuticals (1321834) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 12/09/2025 8:25 AM | Mymd Pharmaceuticals (1321834) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 12/01/2025 4:21 PM | Mymd Pharmaceuticals (1321834) Filer | Form 424B3 | |
| 11/30/2025 11:15 PM | Mymd Pharmaceuticals (1321834) Filer | Form EFFECT | |
| 11/19/2025 4:13 PM | Mymd Pharmaceuticals (1321834) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 11/18/2025 3:29 PM | PharmaCyte Biotech, Inc. (1157075) Filed by Mymd Pharmaceuticals (1321834) Subject | Form SCHEDULE 13D/A | |
| 11/18/2025 3:32 PM | PharmaCyte Biotech, Inc. (1157075) Reporting Mymd Pharmaceuticals (1321834) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/17/2025 4:30 PM | Mymd Pharmaceuticals (1321834) Issuer White Billy Joe (1546805) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/17/2025 4:30 PM | Glass Mitchell (2023649) Reporting Mymd Pharmaceuticals (1321834) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/14/2025 7:16 PM | Mymd Pharmaceuticals (1321834) Issuer Silverman Joshua (1524858) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/14/2025 7:14 PM | Mymd Pharmaceuticals (1321834) Issuer RAUCH GARY M (1597530) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/14/2025 7:15 PM | Bernstein Bruce (1665472) Reporting Mymd Pharmaceuticals (1321834) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/14/2025 7:16 PM | Friscia Stephen (2028845) Reporting Mymd Pharmaceuticals (1321834) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/10/2025 4:26 PM | Mymd Pharmaceuticals (1321834) Filer | Form PRE 14A | |
| 10/06/2025 5:51 PM | Bernstein Bruce (1665472) Reporting Mymd Pharmaceuticals (1321834) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 10/06/2025 4:29 PM | Mymd Pharmaceuticals (1321834) Issuer RAUCH GARY M (1597530) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/06/2025 4:30 PM | Mymd Pharmaceuticals (1321834) Issuer White Billy Joe (1546805) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/06/2025 4:30 PM | Glass Mitchell (2023649) Reporting Mymd Pharmaceuticals (1321834) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/06/2025 4:30 PM | Friscia Stephen (2028845) Reporting Mymd Pharmaceuticals (1321834) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/06/2025 4:30 PM | Mymd Pharmaceuticals (1321834) Issuer Silverman Joshua (1524858) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/06/2025 4:13 PM | Mymd Pharmaceuticals (1321834) Filer | Form 8-K/A | |
| 10/03/2025 4:28 PM | Mymd Pharmaceuticals (1321834) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 10/03/2025 4:29 PM | Mymd Pharmaceuticals (1321834) Filer | Form S-3 Registration statement under Securities Act of 1933 | |
| 09/26/2025 4:10 PM | Mymd Pharmaceuticals (1321834) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 09/10/2025 4:00 PM | Mymd Pharmaceuticals (1321834) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 09/05/2025 4:30 PM | Mymd Pharmaceuticals (1321834) Filer | Form D Notice of Exempt Offering of Securities | |
Elon's new "super startup" (Ad) Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified a new venture quietly incubating inside Tesla. It has nothing to do with EVs, AI, or robotics, yet it generated $12 billion in 2025 alone.
Blackstone calls the broader opportunity a $23 trillion investment runway. Adam believes investors who position themselves before July 22 are early. He's also giving away a free ticker pick in his latest briefing. Watch Adam O'Dell's full briefing and get his free ticker now |
| 09/05/2025 4:30 PM | Mymd Pharmaceuticals (1321834) Filer | Form 8-K/A | |
| 09/02/2025 8:29 AM | Mymd Pharmaceuticals (1321834) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 08/19/2025 4:15 PM | Mymd Pharmaceuticals (1321834) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 08/14/2025 4:01 PM | Mymd Pharmaceuticals (1321834) Filer | Form NT 10-Q | |
| 05/19/2025 4:26 PM | Mymd Pharmaceuticals (1321834) Filer | Form DEFR14A | |